Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narsoplimab - Omeros Corporation

Next Previous
Drug Profile

Narsoplimab - Omeros Corporation

Alternative Names: anti-MASP-2 monoclonal antibody; MASP-2 antibody - Omeros Corporation; MASP-2 therapeutic; Narsoplimab-wuug - Omeros Corporation; OMS 00620646; OMS 620646; OMS 721; YARTEMLEA

Latest Information Update: 12 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Omeros Corporation
  • Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Monoclonal antibodies; Urologics; Vascular disorder therapies
  • Mechanism of Action MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic microangiopathies; IgA nephropathy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Thrombotic microangiopathies
  • Phase II COVID 2019 infections
  • Preclinical Adult respiratory distress syndrome
  • Discontinued Glomerulonephritis; Haemolytic uraemic syndrome; IgA nephropathy; Lupus nephritis; Membranous glomerulonephritis; Stroke; Wet age-related macular degeneration

Most Recent Events

  • 10 Mar 2026 Omeros Corporation terminates phase II clinical trials in Lupus nephritis (Treatment-experienced) in Hong Kong and US, due to sponsor decision (Parenteral) (NCT02682407)
  • 10 Mar 2026 Omeros Corporation terminates phase II clinical trials in Membranous glomerulonephritis (Treatment-experienced) in Hong Kong and US, due to sponsor decision (Parenteral) (NCT02682407)
  • 10 Mar 2026 Omeros Corporation terminates phase II clinical trials in IgA nephropathy (Treatment-experienced) in Hong Kong and US, due to sponsor decision (Parenteral) (NCT02682407)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top